Mirabegron and Localised infection - a phase IV clinical study of FDA data

Summary:

Localised infection is reported as a side effect among people who take Mirabegron (mirabegron), especially for people who are female, 60+ old, have been taking the drug for 1 - 2 years also take Naproxen, and have Neuralgia.

The phase IV clinical study analyzes which people have Localised infection when taking Mirabegron. It is created by eHealthMe based on reports of 5,378 people who have side effects when taking Mirabegron from the FDA, and is updated regularly.

What is Mirabegron?

Mirabegron has active ingredients of mirabegron. It is often used in urge incontinence. eHealthMe is studying from 5,414 Mirabegron users. Check the latest studies of Mirabegron.

What is Localised infection?

Localised infection (infection at the single location) is found to be associated with 1,217 drugs and 918 conditions by eHealthMe. Check the latest studies of Localised infection.

On Aug, 04, 2026

5,378 people reported to have side effects when taking Mirabegron.
Among them, 14 people (0.26%) have Localised infection.

Could Mirabegron cause Localised infection?

Among these 14 people:

How long have people been on Mirabegron when they have Localised infection? *

What is the gender of people who have Localised infection when taking Mirabegron? *

female: 85.71 %
male: 14.29 %

What is the age of people who have Localised infection when taking Mirabegron? *

What are other drugs people take besides Mirabegron? *

What are other side effects people have besides Localised infection? *

Diarrhea: 11 people, 78.57%
Abdominal Pain Upper: 8 people, 57.14%
Back Pain: 8 people, 57.14%
Nausea And Vomiting: 8 people, 57.14%
Joint Swelling: 8 people, 57.14%
Hepatic Neoplasm (liver tumour): 7 people, 50.00%
Back Injury: 7 people, 50.00%
Body Temperature Increased: 7 people, 50.00%
Neuralgia (pain in one or more nerves): 7 people, 50.00%
Sciatic Nerve Injury: 7 people, 50.00%

What are the existing conditions these people have? *

Pain: 7 people, 50.00%
Neuralgia (pain in one or more nerves): 7 people, 50.00%
Carcinoid Tumor: 6 people, 42.86%
Neuroendocrine Carcinoma Metastatic (cancer tumour that arise from cells of the endocrine (hormonal) and nervous systems and spreads to other part): 6 people, 42.86%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 14.29%
Parkinson's Disease: 2 people, 14.29%
Lip Injury: 1 person, 7.14%
Constipation: 1 person, 7.14%
High Blood Pressure: 1 person, 7.14%
Hyperkeratosis (thickening of the outer layer of the skin): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Mirabegron and have Localised infection?

- Check whether Localised infection is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Mirabegron:

Mirabegron (5,414 reports)

Browse all side effects of Mirabegron:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Localised infection:

Localised infection (1,217 drugs)

Browse all the conditions that are associated with Localised infection:

Localised infection (918 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on mirabegron (the active ingredients of Mirabegron) and Mirabegron (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.